FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to oncology, and concerns development of a medicinal agent for angiogenesis control. It is ensured by application of sphingosine-1-phosphate receptor agonist representing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3 diol, or its hydrochloride, or phosphate. The present invention also can include these substances combined with chemotherapeutic agents.
EFFECT: invention provides angiogenesis regulation including inhibition of uncontrolled neoangiogenesis, particularly in solid tumour therapy.
9 cl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
| MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
| S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
| SIP RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | 2007 |
|
RU2495664C2 |
| DERIVATIVES OF ISOTHIOUREA AND METHOD OF THEIR PRODUCTION, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITION | 2005 |
|
RU2376297C2 |
| USE OF RAPAMYCIN DERIVATIVE | 2011 |
|
RU2483727C1 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| CANCER MEDICAL TREATMENT | 2005 |
|
RU2325906C2 |
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2665138C2 |
| NEW COMPOUNDS | 2016 |
|
RU2747645C2 |
